Gritstone bio, Inc. (GRTS)

0.8149 +0.0504 (+6.59%) As of 03:45PM EDT. Market open.

Gritstone bio, Inc.

5959 Horton Street
Suite 300
EmeryVille, CA 94608
United States
510 871 6100
https://gritstonebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 231

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.	Co-Founder, President, CEO & Director	983.44k	N/A	1966
Mr. Erin E. Jones M.S.	Executive VP & COO	658.01k	N/A	1972
Dr. Karin Jooss Ph.D.	Executive VP and Head of Research & Development	706.07k	N/A	1966
Ms. Vassiliki Economides	Executive VP & CFO	N/A	N/A	1981
Mr. James Cho	Chief Accounting Officer	N/A	N/A	N/A
George MacDougall	Director of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Stacy Proctor	Executive VP & Chief People Officer	N/A	N/A	N/A
Dr. Matthew J. Hawryluk M.B.A., Ph.D.	Executive VP & Chief Business Officer	N/A	N/A	1979

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Corporate Governance

Gritstone bio, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 7; Board: 2; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.